Stereotactic Arrhythmia Radioablation as a Novel Treatment Approach for Cardiac Arrhythmias: Facts and Limitations

Q: What is the clinical evidence from this study?

Study design: Systematic Review. Population: Cardiac arrhythmias (ventricular tachycardia and atrial fibrillation) (n=68). Intervention: Stereotactic arrhythmia radioablation (STAR) / Stereotactic ablative radiotherapy (SABR). Primary outcome: Reduction in ventricular tachycardia episodes as monitored by implantable cardioverter-defibrillators (ICDs) and treatment-related serious adverse events (SAEs).

Q: What does this research mean for the field?

Stereotactic arrhythmia radioablation (typically 25 Gy) markedly reduces ventricular tachycardia episodes with minimal serious adverse events in patients refractory to conventional therapies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Marina Chalkia; Vassilis Kouloulias; Dimitris Tousoulis; Spyridon Deftereos; Dimitris Tsiachris; Dimitrios A. Vrachatis; Kalliopi Platoni

doi:10.3390/biomedicines9101461

October 13, 2021BiomedicinesOpen Access

Stereotactic Arrhythmia Radioablation as a Novel Treatment Approach for Cardiac Arrhythmias: Facts and Limitations

View Full Paper

Ask AI

Bookmark

Share

Key result

Stereotactic arrhythmia radioablation reduces VT episodes in nearly all patients with minimal serious adverse events.

n=68

Figures

Why the study?

Stereotactic arrhythmia radioablation has emerged as a novel approach to treat cardiac arrhythmias, prompting a review of its basic principles, clinical outcomes, technique evolution, and quality assurance processes.

Does stereotactic arrhythmia radioablation (STAR) safely reduce arrhythmia episodes in patients with refractory ventricular tachycardia or atrial fibrillation after failed catheter ablation?

Key Points

Review the radiobiological principles, clinical evidence, procedural workflows, and technical challenges of stereotactic arrhythmia radioablation for refractory cardiac arrhythmias.
Narrative review of clinical reports, preclinical models, and procedural protocols for stereotactic ablative radiotherapy in cardiac arrhythmia management.
Evaluation of electroanatomical mapping integration, radiation target motion tracking, organ-at-risk dose constraints, and delivery platforms.
Radioablation successfully induces electrophysiologic conduction blockade and histologic fibrosis, most commonly applying a single-fraction dose of 25 Gy to substantially decrease ventricular tachycardia burden.
Major challenges include motion management during cardiac and respiratory cycles, target proximity to organs-at-risk like the esophagus, and adhering to strict boundaries such as a 20 Gy limit for coronary arteries.
Current evidence remains constrained by small single-center cohorts, short-term follow-up in patients with advanced heart disease, and an absence of standardized quality assurance guidelines.

Study Design

Type

Systematic Review (n=68)

Structured PICO

Does stereotactic arrhythmia radioablation (STAR) safely reduce arrhythmia episodes in patients with refractory ventricular tachycardia or atrial fibrillation after failed catheter ablation?

P

Population

68 adults with refractory ventricular tachycardia (n=62) or atrial fibrillation (n=6) across 39 clinical articles (mean age 65 years, >70% male) with prior catheter ablation failure, followed for 2 to 54 months.

I

Intervention

Stereotactic arrhythmia radioablation (STAR) / stereotactic ablative radiotherapy (SABR), typically delivered as 25 Gy in a single fraction (range 15-25 Gy, or 24 Gy in 3 fractions) using Varian Linac (n=34 VT patients) or Accuray CyberKnife systems alongside background antiarrhythmic drugs (amiodarone, mexiletine, sotalol).

O

Outcome

Primary efficacy endpoint: any reduction in VT episodes as monitored by ICDs (with a blanking period of 1.5-3.0 months and follow-up of 2-54 months). Primary safety endpoint: treatment-related serious adverse events (SAEs) per Common Terminology Criteria for Adverse Events (version 4.0).surrogate

Limitations

Limited number of treated patients reported in the literature (68 patients)
Treatments mostly performed at single centers without multi-center clinical trial validation
Limited long-term follow-up data to assess late radiation-induced cardiac toxicities and long-term arrhythmia recurrence
Narrow pool of eligible patients who mostly had end-stage disease and advanced heart failure
Lack of a standardized quality assurance (QA) protocol and consensus dose constraints for intra-cardiac structures
Limited number of patients
Treatment conducted at single centers
Limited long-term follow-up
Narrow pool of eligible patients with end-stage disease and advanced heart failure
Lack of standardized quality assurance (QA) protocols and consensus dose constraints for intra-cardiac substructures

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Stereotactic arrhythmia radioablation (STAR) shows promising initial efficacy and acceptable short-term safety as a noninvasive bailout therapy for refractory ventricular tachycardia, though standardized quality assurance protocols and long-term multi-center data are needed.

Abstract

Stereotactic ablative radiotherapy (SABR) is highly focused radiation therapy that targets well-demarcated, limited-volume malignant or benign tumors with high accuracy and precision using image guidance. Stereotactic arrhythmia radioablation (STAR) applies SABR to treat cardiac arrhythmias, including ventricular tachycardia (VT) and atrial fibrillation (AF), and has recently been a focus in research. Clinical studies have demonstrated electrophysiologic conduction blockade and histologic fibrosis after STAR, which provides a proof of principle for its potential for treating arrhythmias. This review will present the basic STAR principles, available clinical study outcomes, and how the technique has evolved since the first pre-clinical study. In addition to the clinical workflow, focus will be given on the process for stereotactic radiotherapy Quality Assurance (QA) tests, as well as the need for establishing a standardized QA protocol. Future implications and potential courses of research will also be discussed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chalkia et al. (2021) conducted a systematic review in Cardiac arrhythmias (ventricular tachycardia and atrial fibrillation) (n=68). Stereotactic arrhythmia radioablation (STAR) / Stereotactic ablative radiotherapy (SABR) was evaluated on Reduction in ventricular tachycardia episodes as monitored by implantable cardioverter-defibrillators (ICDs) and treatment-related serious adverse events (SAEs).

synapsesocial.com/papers/6a75b699bff0e42c1b1611fd https://doi.org/10.3390/biomedicines9101461

View Full Paper

Ask AI

Bookmark

Share

Stereotactic Arrhythmia Radioablation as a Novel Treatment Approach for Cardiac Arrhythmias: Facts and Limitations

Figures

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Stereotactic Arrhythmia Radioablation as a Novel Treatment Approach for Cardiac Arrhythmias: Facts and Limitations

Figures

Key Points

Study Design

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading